Thermo Fisher Scientific

While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said. 

The company reported $4.77 billion in first quarter revenues, driven by growth in all of its business segments.

The companies will work together to secure US approval for SpeeDx's antibiotic-resistant Mycoplasma genitalium assay.

Thermo is launching a program to develop its NGS Oncomine products into companion diagnostics, with the University Hospital Basel as its first partner.

GenDx is planning to get CE marking for an Ion Torrent-based HLA typing workflow, to add to the firm's set of NGS solutions for transplant diagnostics.

Eleven laboratories that are part of Thermo's OncoNetwork Consortium tested the Oncomine Lung cfDNA assay on reference samples.

The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.

The list includes "high throughput DNA sequence analyzer," "DNA genetic analyzer," and "mass spectrometer for clinical multiplex test systems." 

The company said it will use the net proceeds to redeem the outstanding $500 million aggregate principal amount of senior notes maturing in January 2018.

The Thermo Fisher subsidiary is not liable to Promega in the US for selling infringing forensic DNA kits in Europe, containing US-manufactured Taq polymerase.

Pages

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.